Teriflunomide Patent Expiration
Teriflunomide is Used for treating patients with relapsing forms of multiple sclerosis. It was first introduced by Sanofi Aventis Us Llc
Teriflunomide Patents
Given below is the list of patents protecting Teriflunomide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aubagio | US5459163 | Medicament to combat autoimmune diseases |
Oct 17, 2012
(Expired) | Sanofi Aventis Us |
| Aubagio | US5679709 | Medicaments to combat autoimmune diseases |
Oct 21, 2014
(Expired) | Sanofi Aventis Us |
| Aubagio | US6794410 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis | Sep 12, 2026 | Sanofi Aventis Us |
| Aubagio |
US6794410 (Pediatric) | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis | Mar 12, 2027 | Sanofi Aventis Us |
| Aubagio | US8802735 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability | Sep 14, 2030 | Sanofi Aventis Us |
| Aubagio |
US8802735 (Pediatric) | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability | Mar 14, 2031 | Sanofi Aventis Us |
| Aubagio | US9186346 | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients | Feb 04, 2034 | Sanofi Aventis Us |
| Aubagio |
US9186346 (Pediatric) | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients | Aug 04, 2034 | Sanofi Aventis Us |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Teriflunomide Generics
Several generic applications have been filed for Teriflunomide. The first generic version for Teriflunomide was by Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc and was approved on Jul 27, 2018. And the latest generic version is by Torrent Pharma Inc and was approved on Apr 4, 2024.
Given below is the list of companies who have filed for Teriflunomide generic.
1. TORRENT
Torrent Pharma Inc has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Torrent.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 14MG | tablet | Prescription | ORAL | AB | Apr 4, 2024 |
| 7MG | tablet | Prescription | ORAL | AB | Apr 4, 2024 |
2. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 14MG | tablet | Prescription | ORAL | AB | Jan 7, 2019 |
| 7MG | tablet | Prescription | ORAL | AB | Jan 7, 2019 |
3. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 7MG | tablet | Discontinued | ORAL | N/A | Feb 28, 2020 |
| 14MG | tablet | Discontinued | ORAL | N/A | Feb 28, 2020 |
4. BIOCON PHARMA
Biocon Pharma Ltd has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Biocon Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 7MG | tablet | Prescription | ORAL | AB | Mar 13, 2023 |
| 14MG | tablet | Prescription | ORAL | AB | Mar 13, 2023 |
5. TEVA PHARMS USA
Teva Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 14MG | tablet | Prescription | ORAL | AB | Sep 4, 2018 |
| 7MG | tablet | Prescription | ORAL | AB | Sep 4, 2018 |
6. GLENMARK SPECLT
Glenmark Specialty Sa has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Glenmark Speclt.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 14MG | tablet | Prescription | ORAL | AB | Nov 15, 2018 |
| 7MG | tablet | Prescription | ORAL | AB | Nov 15, 2018 |
7. SANDOZ
Sandoz Inc has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 7MG | tablet | Prescription | ORAL | AB | Jan 3, 2019 |
| 14MG | tablet | Prescription | ORAL | AB | Jan 3, 2019 |
8. NATCO
Natco Pharma Ltd has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Natco.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 7MG | tablet | Prescription | ORAL | AB | May 15, 2023 |
| 14MG | tablet | Prescription | ORAL | AB | May 15, 2023 |
9. HETERO LABS LTD V
Hetero Labs Ltd Unit V has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd V.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 14MG | tablet | Prescription | ORAL | AB | Mar 13, 2023 |
| 7MG | tablet | Prescription | ORAL | AB | Mar 13, 2023 |
10. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 7MG | tablet | Prescription | ORAL | AB | Nov 30, 2018 |
| 14MG | tablet | Prescription | ORAL | AB | Nov 30, 2018 |
11. MSN
Msn Laboratories Private Ltd has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Msn.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 14MG | tablet | Prescription | ORAL | AB | Apr 24, 2019 |
| 7MG | tablet | Prescription | ORAL | AB | Apr 24, 2019 |
12. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Breckenridge.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 14MG | tablet | Discontinued | ORAL | N/A | Sep 24, 2021 |
| 7MG | tablet | Discontinued | ORAL | N/A | Sep 24, 2021 |
13. SOLA PHARMS
Sola Pharmaceuticals has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Sola Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 14MG | tablet | Prescription | ORAL | AB | Jun 17, 2020 |
| 7MG | tablet | Prescription | ORAL | AB | Sep 28, 2023 |
14. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 7MG | tablet | Prescription | ORAL | AB | Apr 19, 2019 |
| 14MG | tablet | Prescription | ORAL | AB | Apr 19, 2019 |
15. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 14MG | tablet | Prescription | ORAL | AB | Oct 26, 2018 |
| 7MG | tablet | Prescription | ORAL | AB | Oct 26, 2018 |
16. APOTEX
Apotex Inc has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 7MG | tablet | Prescription | ORAL | AB | Nov 2, 2018 |
| 14MG | tablet | Prescription | ORAL | AB | Nov 2, 2018 |
17. AMNEAL PHARMS CO
Amneal Pharmaceuticals Co Gmbh has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Amneal Pharms Co.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 14MG | tablet | Discontinued | ORAL | N/A | Sep 28, 2018 |
| 7MG | tablet | Discontinued | ORAL | N/A | Sep 28, 2018 |
18. WATSON LABS TEVA
Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Teriflunomide. Given below are the details of the strengths of this generic introduced by Watson Labs Teva.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 7MG | tablet | Discontinued | ORAL | N/A | Jul 27, 2018 |
| 14MG | tablet | Discontinued | ORAL | N/A | Jul 27, 2018 |